PDF(Pubmed)
Abstract：
Iruplinalkib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with efficacy in patients with ALK-positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC), which is independently developed by a Chinese pharmaceutical company. This study examined the cost-effectiveness of iruplinalkib versus alectinib in the Chinese healthcare setting.
A partitioned survival model was developed to project the economic and health outcomes. Efficacy was derived using unanchored matching-adjusted indirect comparison (MAIC). Cost and utility values were obtained from the literature and experts\' opinions. Deterministic and probabilistic sensitivity analyses (PSA) were carried out to evaluate the model\'s robustness.
Treatment with iruplinalkib versus alectinib resulted in a gain of 0.843 quality-adjusted life years (QALYs) with incremental costs of $20,493.27, resulting in an incremental cost-effectiveness ratio (ICER) of $24,313.95/QALY. Parameters related to relative efficacy and drug costs were the main drivers of the model outcomes. From the PSA, iruplinalkib had a 90% probability of being cost-effective at a willingness-to-pay threshold of $37,863.56/QALY.
Compared to alectinib, iruplinalkib is a cost-effective therapy for patients with ALK-positive crizotinib-resistant advanced NSCLC.
A partitioned survival model was developed to project the economic and health outcomes. Efficacy was derived using unanchored matching-adjusted indirect comparison (MAIC). Cost and utility values were obtained from the literature and experts\' opinions. Deterministic and probabilistic sensitivity analyses (PSA) were carried out to evaluate the model\'s robustness.
Treatment with iruplinalkib versus alectinib resulted in a gain of 0.843 quality-adjusted life years (QALYs) with incremental costs of $20,493.27, resulting in an incremental cost-effectiveness ratio (ICER) of $24,313.95/QALY. Parameters related to relative efficacy and drug costs were the main drivers of the model outcomes. From the PSA, iruplinalkib had a 90% probability of being cost-effective at a willingness-to-pay threshold of $37,863.56/QALY.
Compared to alectinib, iruplinalkib is a cost-effective therapy for patients with ALK-positive crizotinib-resistant advanced NSCLC.
摘要：
■Iruplinalkib是第二代间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKI），对ALK阳性克唑替尼耐药的晚期非小细胞肺癌（NSCLC）患者有效，由一家中国制药公司自主研发。这项研究检查了伊鲁替尼与阿来替尼在中国医疗保健环境中的成本效益。
■开发了分区生存模型来预测经济和健康结果。使用非锚定匹配调整的间接比较(MAIC)得出功效。成本和效用值是从文献和专家的意见中获得的。进行了确定性和概率敏感性分析(PSA)来评估模型的稳健性。
■伊龙替尼与阿莱替尼治疗相比，质量调整生命年（QALYs）增加了0.843个，增加的成本为20,493.27美元，增加的成本效益比（ICER）为24,313.95美元/QALY。与相对疗效和药物成本相关的参数是模型结果的主要驱动因素。从PSA,在37,863.56美元/QALY的支付意愿门槛下，iruplinalkib有90%的可能性具有成本效益。
■与阿来替尼相比，伊立铂是ALK阳性克唑替尼耐药的晚期NSCLC患者的一种经济有效的治疗方法。
■开发了分区生存模型来预测经济和健康结果。使用非锚定匹配调整的间接比较(MAIC)得出功效。成本和效用值是从文献和专家的意见中获得的。进行了确定性和概率敏感性分析(PSA)来评估模型的稳健性。
■伊龙替尼与阿莱替尼治疗相比，质量调整生命年（QALYs）增加了0.843个，增加的成本为20,493.27美元，增加的成本效益比（ICER）为24,313.95美元/QALY。与相对疗效和药物成本相关的参数是模型结果的主要驱动因素。从PSA,在37,863.56美元/QALY的支付意愿门槛下，iruplinalkib有90%的可能性具有成本效益。
■与阿来替尼相比，伊立铂是ALK阳性克唑替尼耐药的晚期NSCLC患者的一种经济有效的治疗方法。
